Heme oxygenase-1 (HO-1) catalyses the degradation of heme to biliverdin, free iron, and carbon monoxide. The promoter region contains a highly polymorphic (GT) n repeat, where shorter (GT) n repeat sequences are linked to higher transcriptional activity, which was shown to correlate with a cytoprotective effect. Higher HO-1 levels may protect from cardiac allograft vasculopathy. Cardiac allograft recipients transplanted between 1988 and 2012 were analyzed for the HO-1 (GT) n repeat polymorphism using PCR and DNA fragment analysis with capillary electrophoresis. A relation to cardiac allograft vasculopathy (CAV) was analyzed using Cox regression including common risk factors for CAV and the occurrence of rejection episodes as explanatory variables. A total of 344 patients were analyzed, of which 127 patients were positive for CAV (36.9%). In our multivariable Cox regression analysis, the short homozygous HO-1 (GT) n genotype with <27 repeats (S/S) revealed a higher risk for CAV (P = 0.032). Donor age (P = 0.001) and donor weight (P = 0.005) were significant predictors for CAV. A potential risk for CAV was associated with rejection episodes (P = 0.058) and history of smoking (P = 0.06). The recipient HO-1 (GT) n genotype may contribute to CAV development. This finding has to be evaluated in larger series including studies targeting the underlying disease mechanism.
Introduction
Heme oxygenase (HO) catalyses the rate-limiting step in the degradation of heme to biliverdin, free iron, and carbon monoxide [1] . Three isoforms of HO have been described; the inducible isoform HO-1 is found mainly in the liver and spleen, but it is also located in numerous other tissues including the heart, lung, brain, vascular smooth muscle cells, and endothelial cells [2, 3] . Stimuli for induction include its substrate heme, heat shock proteins, and cellular stress, such as oxidative stress and exposure to ultraviolet light [4] . The region upstream of the transcription initiation site of the HO-1 gene, including the promoter region, contains a highly polymorphic poly[d(T-G)] element [5, 6] . This (GT) n length polymorphism has been shown to be linked to the transcriptional activity of the gene, where longer (GT) n repeat sequences resulted in lower transcriptional activity, and shorter (GT) n repeat sequences resulted in higher transcriptional activity [7, 8] . Higher transcriptional activity was shown to correlate with a protective effect regarding the occurrence of cardiovascular disease, but the relevance of the HO-1 (GT) n length polymorphism has also been questioned by studies that were not able to determine a statistically significant association between coronary artery disease and the HO-1 (GT) n repeat allele status [7, [9] [10] [11] [12] [13] .
Cardiac allograft vasculopathy is characterized by diffuse luminal narrowing, affecting epicardial and intramyocardial arteries and veins, and presenting an accelerated progression compared to traditional atherosclerosis [14] . One year after heart transplantation, 10% of recipients are diagnosed with CAV, the incidence rising to more than 50% of recipients 10 years after transplant [15] . Although the incidence of CAV has decreased in patients receiving an allograft between 2003 and 2010 when compared to patients receiving an allograft between 1994 and 2003 (37% and 42%, respectively), CAV remains one of the leading causes of death in this patient population, particularly more than 3 years after transplant [15] . The traditional risk factors for CAV include male gender, hyperlipidemia, hypertension, obesity, diabetes, and metabolic syndrome, and are thus similar to the risk factors for traditional atherosclerosis [14, 16, 17] . Transplant-associated risk factors for CAV include cytomegalovirus (CMV) infection, immunological factors such as HLA antigen mismatch and cellular and antibody-mediated rejection episodes, and donor factors such as donor age, explosive brain death and intracranial hemorrhage [15, 16] . The early diagnosis of CAV is critical to ensure appropriate treatment, but the denervated allograft often prevents typical signs of ischemia such as chest pain [16, 18] . Coronary angiography is currently the standard diagnostic tool, but may underestimate the extent of CAV due to the characteristic diffuse luminal narrowing [16, 18] . Intravascular ultrasound (IVUS) has proven to be a sensitive surrogate marker for the diagnosis of CAV, allowing the exact definition of the lumen diameter as well as the morphology of the intima [16, 18, 19] . As a noninvasive test, dobutamine stress echocardiography is available for screening purposes. Biomarkers such as C-reactive protein (CRP), brain natriuretic peptide (BNP), troponin I, and von Willebrand factor can be used to complete the clinical information on a patient, but are currently not used as predictors of CAV [16, 18] . It is, therefore, highly desirable to develop a new noninvasive test to serve as a predictor of CAV.
We aimed to determine whether the HO-1 (GT) n length polymorphism in heart transplant recipients can be linked to the occurrence of CAV. This genetic polymorphism could serve as a potential predictive biomarker for CAV, possibly providing a new noninvasive method for risk stratification of heart transplant patients for CAV.
Materials and methods

Patient population
Patients were consented to participate in the Medical University of Vienna Heart Transplant Biobank project to provide blood samples in the course of their scheduled clinic visits at the Vienna General Hospital between 2009 and 2012. The patients' demographic and clinical data were collected in a prospective institutional transplant database and analyzed for this project. Coronary angiographies are performed at standard intervals after cardiac transplantation, namely 1, 5, and 10 years after transplantation, or whenever clinically indicated. All available coronary angiographies within follow-up were used to evaluate the patients for CAV, defined according to the standardized nomenclature of the International Society for Heart and Lung Transplantation (ISHLT): "ISHLT CAV 0 (not significant) is defined as no detectable angiographic lesion; ISHLT CAV 1 (mild) is defined as angiographic left main <50%, or primary vessel with maximum lesion of <70%, or any branch stenosis <70% (including diffuse narrowing) without allograft dysfunction; ISHLT CAV 2 (moderate) is defined as angiographic left main <50%, a single primary vessel ≥70%, or isolated branch stenosis ≥70% in branches of two systems, without allograft dysfunction; ISHLT CAV 3 is defined as angiographic left main ≥50%, or two primary vessels ≥70% stenosis, or isolated branch stenosis ≥70% in all three systems, or ISHLT CAV 1 or CAV 2 with allograft dysfunction (defined as left ventricular ejection fraction, LVEF, ≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology" [19] . Cardiac allograft recipients were further evaluated for common risk factors such as a previous history of smoking, diabetes mellitus type 2, alcohol abuse, ischemic time, the underlying disease and CMV risk. Rejection episodes were classified as defined by the ISHLT standardized nomenclature [20] .
HO-1 (GT) n genotype assessment DNA extraction from whole blood samples was performed according to standard guidelines, using the E.Z.N.A.
â Blood DNA Mini Kit (Omega Bio-Tek, Norcross, GA, USA). For the HO-1 (GT) n length polymorphism assessment, DNA was amplified by PCR followed by DNA fragment analysis with capillary electrophoresis, according to the protocol described by Doberer et al. [21] . The samples were grouped into genotype classes according to the number of (GT) n repeats, where samples with fewer than 27 repeats were included in "class S" [short (S), GT <27] and samples with 27 or more repeats were included in "class L" [long (L), GT ≥27], resulting in the three genotype classes homozygous S/S, homozygous L/L and heterozygous S/L, as previously described [21] .
Statistical analysis
Descriptive statistical methods were applied to depict the study population regarding preoperative risk factors. Continuous variables were presented as mean and standard deviation, total numbers, and proportions were reported for categorical variables. The inverse Kaplan-Meier method was used to calculate the median follow-up time [22] . The time to first positive CAV evaluation after heart transplantation, irrespective of CAV severity as categorized according to the ISHLT standardized nomenclature [19] , was considered as the primary outcome variable. Patients without angiographically positive CAV evaluation were classified as negative for CAV and censored at the last follow-up date. To estimate the probability of developing CAV, the cumulative incidence function (CIF) was calculated accounting for death as a competing risk event. Gray's test was used to test for differences between groups of patients. Univariate and multivariable Cox regression analyses were performed, evaluating the correlation of the HO-1 (GT) n genotype and other common risk factors for CAV with the incidence of CAV. Patients, who died without previous CAV, were considered as censored observations. Within these Cox regression models, the prognostic factor rejection was considered as a time-dependent variable. Furthermore, possible time-varying effects of the considered risk factors were tested and included in the multivariable regression model in case of statistical significance. A P-value ≤0.05 was considered as indicating statistical significance. SAS version 9.4 (2002-2012; SAS Institute Inc., Cary, NC, USA) was applied for all analyses.
Results
Patient characteristics
A total of 344 heart transplant recipients were analyzed, including 272 male patients and 72 female patients (79% and 21%, respectively, see Table 1 ). The median age of the cardiac allograft donors was 34 years, ranging from 10 to 70 years, while the median age of the cardiac allograft recipients was 54 years, ranging from 9 to 73 years. The median follow-up time was 187 months. 
HO-1 repeat polymorphism
The analysis of the HO-1 repeat polymorphism showed a total of 21 repeat alleles, ranging from 17 repeats to 39 repeats, with 30 being the most common repeat allele. The alleles were grouped into genotype classes as described above [short (S), GT <27; long (L), GT ≥27; (Fig. 1) . The difference was not statistically significant (P = 0.105).
In the univariate Cox regression analysis, no statistical significance could be defined for the overall effect of the three genotype classes on the development of CAV (P = 0.088, see Table 3 ). However, in our multivariable model, the homozygous S/S (GT) n repeat genotype class revealed a higher risk for CAV (P = 0.0316), where the L/L class compared to the S/S class showed a hazard ratio of 0.520 (95% CI 0.302-0.895) and the S/L class compared to the S/S class showed a hazard ratio of 0.509 (95% CI 0.300-0.865, see Table 4 ).
Common risk factors for CAV
Calculating the cumulative incidence function, the likelihood of developing CAV after transplantation was shown to be 2.3% after 1 year (95% CI 1.1-4.4%), 24.5% after 10 years (95% CI 19.8-29.6%), 51.5% after 20 years (95% CI 43.8-58.7%), and 62.5% after 30 years (95% CI 52.2-71.1%). Comparing the cumulative incidence functions with respect to preoperative patient characteristics, only diabetes mellitus type 2 (P = 0.031), donor age (categorized at the median age: P = 0.022), and recipient weight (categorized at the median weight: P = 0.005) could be shown to have a statistically significant effect on the incidence of CAV.
In the univariate Cox regression analysis, a time-dependent effect could be seen of donor weight on the incidence of CAV (P = 0.0003, see Table 3 ). The statistically significant effect of diabetes mellitus (P = 0.039), donor age (P < 0.001), and recipient weight (P = 0.016) on the development of CAV was confirmed in the univariate model. The occurrence of a moderate (grade 2R) or severe rejection (grade 3R) episode showed a potential risk for CAV (P = 0.064).
In the multivariable Cox regression model, donor age showed a statistically significant effect on the development of CAV (P = 0.001, see Table 4 ). A time-dependent effect of donor weight on the development of CAV was seen, where the effect diminished over time (P = 0.005). History of rejection episodes again revealed a potential risk for CAV (P = 0.058), as well as a history of smoking (P = 0.060). No statistically significant independent association was found concerning the incidence of CAV and recipient sex, donor sex, diabetes, recipient weight, donor height, recipient height, left ventricular ejection fraction, CMV risk, or ischemia time.
Discussion
Previous studies were not able to show an association between the HO-1 (GT) n genotype and the manifestation of cardiac allograft vasculopathy [23, 24] . In our multivariable Cox model, we could show a statistically significant effect of the HO-1 genotype on CAV development when corrected for common risk factors, where the homozygous short (GT) n length polymorphism group (S/S) revealed a higher risk for CAV L/L, long/long; S/S, short/short; S/L, short/long; f, female; m, male; CMV, cytomegalovirus.
Data expressed as hazard ratio (HR) and 95% confidence interval (CI).
development. We were able to show an opposite effect compared to prior results describing the S/S polymorphism as a protective variant in several settings. It has been shown that the overexpression of HO-1 in rat aorta chronic rejection models resulted in the inhibition of chronic rejection and the prevention of graft arteriosclerosis, implying a beneficial effect of HO-1 on the long-term function of cardiac allografts, raising the question whether the HO-1 (GT) n length polymorphism and the related transcriptional activity may have an impact on long-term survival [25, 26] . Unfortunately, these findings could not be verified in humans, where the analysis of the HO-1 (GT) n length polymorphism in endomyocardial biopsies of allografts did not show a significant difference in the frequency of CAV or mortality [24] . Holweg et al. [23] , who analyzed both donor and recipient DNA, were not able to show a statistically significant difference in the frequency of CAV, defined as abnormalities in a coronary angiogram 1 year after transplantation. Considering this, we analyzed the allele status of allograft recipients and used the standardized nomenclature as defined by the ISHLT to describe the clinical onset of CAV, which takes into account both angiographic lesions and allograft dysfunction as defined by a LVEF ≤45% [19] . Furthermore, we were able to analyze a larger patient population with a longer followup time after transplantation.
Chen et al. [27] evaluated more than 2000 patients with coronary heart disease and their matched controls for the HO-1 (GT) n genotype, showing that subjects carrying a S/S (GT) n genotype were less likely to have coronary heart disease, especially in subjects with high levels of oxidative stress as seen by elevated levels of plasma malonaldehyde. Additionally, lower transcriptional activity of the HO-1 gene was observed more frequently in type 2 diabetic patients with coronary artery disease, suggesting that elevated oxidative stress levels and decreased HO-1 levels may contribute to the development of coronary artery disease [7, 28] . However, high levels of oxidative stress were required for high levels of HO-1 expression in subjects carrying the S/S (GT) n genotype, and lower levels of oxidative stress did not affect HO-1 levels regardless of the genotype class [27] . In 2013, White et al. [29] analyzed cardiac transplantation recipients for plasma biomarkers of oxidative stress using enzyme-linked immunosorbent assay (ELISA), showing that peak levels were reached early on in the post-transplant phase (weeks 2-4), thereafter decreasing to reach a plateau. This characteristic oxidative stress pattern after cardiac transplantation may indicate chronic dysregulation in the development of CAV rather than acute ischemic damage, a process in which HO-1 activity may not be implicated. L/L, long/long; S/S, short/short; S/L, short/long; f, female; m, male; CMV, cytomegalovirus. Data expressed as hazard ratio (HR) and 95% confidence interval (CI).
Recently, the analysis of HO-1 mRNA and protein levels in serum, liver and adipose biopsies from obese insulin-resistant and obese insulin-sensitive individuals showed that obese insulin-resistant individuals were exposed to higher HO-1 expression levels than insulinsensitive individuals, and the HO-1 expression levels served as positive predictors of metabolic dysregulation [30] . As these findings were contradictory to expectancies, the same group used mouse HO-1 deletion models to verify these results, which showed that the deletion of HO-1 in hepatocytes led to normal metabolic regulation as determined by glucose and insulin tolerance, indicating a driving role of HO-1 in the development of metabolic inflammation and metabolic disease [30] . These results indicate an effect similar to the results we were able to show in our model, clearly indicating the necessity of further research regarding the interplay of HO-1 and inflammatory pathways, potentially with the notion that the loss of HO-1 actually has an antiinflammatory effect.
The multitude of effects associated with HO-1 and its by-products, particularly free iron, bilirubin, biliverdin, and carbon monoxide, observed in vitro and in vivo in animal studies, results in an array of consequences that have all been shown to affect the pathogenesis of human diseases [4, [31] [32] [33] [34] . The protective effects observed in relation to HO-1 and the heme degradation pathway have been linked to the collaboration of various immune factors including macrophage migration inhibitory factor, TNF-alpha, TGF-beta 1, IL-4, IL-10, IL-17 and the complement system [33] [34] [35] [36] [37] [38] . Additional research is required to further define the interplay among these factors and thus elicit the precise role of HO-1.
In addition to the HO-1 (GT) n repeat polymorphism, it has been shown that a À413A>T single nucleotide polymorphism in the promoter region of the gene may also affect the development of coronary artery disease [39] . The HO-1 (GT) n repeat polymorphism that we analyzed for this study may, therefore, not be the only genetic polymorphism responsible for the regulation of the transcriptional activity of HO-1, along with other yet undefined genetic or epigenetic factors. Interestingly, L€ ublinghoff et al. [40] analyzed both the HO-1 (GT) n repeat polymorphism and the À413A>T single nucleotide polymorphism, but were not able to demonstrate a correlation with the development of coronary artery disease. Thus, it is possible that the HO-1 (GT) n genotype alone is not sufficient as a risk factor for coronary artery disease.
It is established that CAV is correlated with a combination of traditional vascular risk factors and transplant-associated risk factors. In our study, we took into account a number of common risk factors for the development of CAV, including donor age, donor weight, donor height, recipient age, recipient weight, recipient height, left ventricular ejection fraction prior to transplantation, time from transplant to diagnosis, ischemia time, rejection episodes, diabetes, and smoking. The univariate Cox regression analysis showed a statistically significant effect of donor age, donor weight, recipient weight, and diabetes mellitus on the development of CAV, with a borderline significant effect of the occurrence of rejection episodes. Additionally, donor weight and donor age were statistically significant predictors of CAV in our multivariable Cox model, with borderline significant effects of rejection episodes and history of smoking. The multitude of risk factors implicated in the development of CAV presents a confounding factor that may influence the results of studies performed, as well as the medication regimen including immunosuppressive drugs, and the effects of these aspects needs to be evaluated in a larger series to determine their position in the development of CAV [16] .
At our institution, coronary angiography is routinely performed 1, 5 and 10 years after cardiac transplantation, or whenever clinically indicated. Therefore, important data on the timeline of CAV development may be missed, patients may be classified as CAV negative because the diagnosis has not yet been made if the patient is asymptomatic, and patients with severe CAV may die prior to diagnosis. Additionally, evidence has been presented that coronary angiography may underestimate the extent of CAV and thus provide false negative results in the diagnosis of CAV, suggesting the requirement of more sensitive methods such as IVUS [16, 18, 41] .
Taken together, evidence suggest that it is highly probable that there are several factors influencing the development of cardiac allograft vasculopathy after heart transplantation, which are not likely be traced to the HO-1 (GT) n genotype alone. Further studies need to be conducted to increase the understanding of the underlying mechanism of the development of CAV. The impact of the various genetic polymorphisms found in the HMOX1 gene on the transcriptional activity of HO-1 and thus the actual levels of HO-1 found in the bloodstream, and finally the interaction between HO-1, oxidative stress, and the development of CAV remains to be determined.
Conclusion
In our patient population, the multivariable Cox regression analysis revealed a statistically significant effect of the HO-1 (GT) n length polymorphism on the development of cardiac allograft vasculopathy, where the homozygous short group was associated with a higher risk for CAV (P = 0.032). These results are contradictory to results presented in previous studies, which either showed evidence for a protective effect of the short (GT) n length polymorphism group on the development of CAV, or no statistically significant effect of the (GT) n length genotype on the development of CAV. This finding has to be evaluated in a larger series including studies targeting the underlying disease mechanism, to provide further evidence whether the HO-1 (GT) n genotype could be used as a reliable marker for cardiac allograft vasculopathy.
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